CD33 detection by immunohistochemistry in paraffin-embedded tissues: A new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage

American Journal of Clinical Pathology

Volumn 129, Issue 2, 2008, Pages 316-323

  Hoyer, James D ^a   Grogg, Karen L ^a   Hanson, Curtis A ^a   Gamez, Jeffrey D ^a   Dogan, Ahmet ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute leukemia; CD33; Flow cytometry; Immunohistochemistry

Indexed keywords

CD33 ANTIBODY; CELL ANTIBODY; PARAFFIN; BIOLOGICAL MARKER; CD33 ANTIGEN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE LEUKEMIA; ANTIGEN ANTIBODY REACTION; ANTIGEN DETECTION; ARTICLE; BONE MARROW DISEASE; FLOW CYTOMETRY; GRANULOCYTE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MONOCYTE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; ANTIBODY SPECIFICITY; BONE MARROW; COMPARATIVE STUDY; EVALUATION; GRANULOCYTIC SARCOMA; IMMUNOLOGY; LYMPHATIC LEUKEMIA; MYELOID LEUKEMIA; REPRODUCIBILITY;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; BONE MARROW; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID; PARAFFIN EMBEDDING; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REPRODUCIBILITY OF RESULTS; SARCOMA, MYELOID; TISSUE ARRAY ANALYSIS;

EID: 40449110688     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/E36008Y2H08Q1AYY     Document Type: Article

References (18)

1. Freeman SD, Kelm S, Barber EK, et al. Characterization of CD33 as a new member of the sialoadhesion family of cellular interaction molecules. Blood. 1995;85:2005-2012.
2. Powell LD, Varki A. I-type lectins. J Biol Chem. 1995;270:14243-14246.
3. Crocker, PR. Siglecs: sialic-acid binding immunoglobulin-like lectins in cell-cell interactions and signaling. Curr Opin Struct Biol. 2002;12:609-615.
4. Crocker PR, Zhang J. New I-type lectins of the CD33-related siglec subgroup identified through genomics. Biochem Soc Symp. 2002;69:83-96.
5. Peiper SC, Ashmun RA, Look AT. Molecular cloning, expression and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood. 1988;72:314-321.
6. Borowitz, MJ, Guenther KL, Shults KE, et al. Immunophenotyping of acute leukemia by flow cytometric analysis: use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol. 1993;100:534-540.
7. Stasi R, Taylor CG, Venditti A, et al. Contribution of immunophenotyping and genotypic analyses to the diagnosis of acute leukemia. Ann Hematol. 1995;71:13-27.
8. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood. 1997;90:2863-2892.
9. Braylan RC, Orfao A, Borowitz MJ, et al. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. Cytometry. 2001;46:23-27.
10. Chang H, Salma F, Yi QL, et al. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res. 2004;28:43-48.
11. Mason KD, Juneja SK, Szer J. The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? Blood Rev. 2006;20:71-78.
12. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678-3684.
13. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer. 2003;98:2095-2104.
14. Sperr WR, Florian S, Hauswirth AW, et al. CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. Leuk Lymphoma. 2005;46:1115-1120.
15. Golay J, DiGaetano N, Amico D, et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33-positive acute lymphoblastic leukemia in vitro and in vivo. Br J Haematol. 2005;128:310-317.
16. Zwaan CM, Reinhardt D, Jürgens H, et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin [letter]. Leukemia. 2003;17:468-470.
17. Baroni CD, Vitolo D, Remotti D, et al. Immunohistochemical heterogeneity of macrophage subpopulations in human lymphoid tissues. Histopathology. 1987;11:1029-1042.
18. Robillard N, Wuillème S, Lode C, et al. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target [letter]. Leukemia. 2005;19:2021-2022.